Radioactive drug lutathera takes on brain cancer in early trial

NCT ID NCT05109728

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 1 trial tests a radioactive drug called Lutathera in people with glioblastoma, an aggressive brain cancer. The study includes two groups: newly diagnosed patients receiving Lutathera with standard radiation and chemotherapy, and patients with recurrent glioblastoma receiving Lutathera alone. The main goal is to find the safest dose and check for side effects. About 65 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutathera (lutetium Lu 177 dotatate)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for glioblastoma, a difficult-to-treat brain cancer.
What could go wrong: This is an early phase 1 trial with only 65 participants, focused on safety and dosing. It is too soon to know if the treatment will be effective or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Col Uni Med Center New York Presby

New York, New York, 10032, United States
MD Anderson Cancer Center Uni of Te

Houston, Texas, 77030, United States
Novartis Investigative Site

Bron, 69677, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Porto, 4200-072, Portugal
Novartis Investigative Site

Granada, Andalusia, 18014, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Madrid, 28050, Spain
Novartis Investigative Site

Lausanne, 1011, Switzerland
Novartis Investigative Site

Zurich, 8091, Switzerland
University of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States
University of Wisconsin School of Medicine and Public Health

Madison, Wisconsin, 53792-1615, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.